20 hours ago · Metsera Inc. raised $275 million in its IPO, selling 15.3 million shares for $18 each, according to a statement. ... Also on Thursday, Maze Therapeutics Inc. priced an upsized IPO at $16 a share ...

1 day ago · Maze, a maker of kidney disease medicines, priced more than 8.7 million shares at $16 each, exceeding the terms it had set earlier this week. Metsera shares will trade on the Nasdaq Friday under the symbol “MTSR,” while Maze’s stock will be listed under “MAZE.” Metsera’s offering completes a quick jump to public markets.

20 hours ago · Metsera Inc. raised $275 million in its IPO, selling 15.3 million shares for $18 each, according to a statement Bloomberg Terminal It had offered 17.2 million shares for $15 to $17 each.

10 hours ago · Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

21 hours ago · New York City-based Metsera sold 15.28 million shares above its targeted range at $18 apiece. The company had initially marketed 17.19 million shares at a range of $15 to $17 each.

3 days ago · On the same day as Metsera’s filing, Maze Therapeutics also outlined plans for a $131m Nasdaq IPO, while Ascentage Pharma – already listed in Hong Kong – started trading in the US last week ...

4 days ago · Metsera Inc. is seeking to raise $292 million in an initial public offering, joining a clutch of health-care firms set to make their debuts as public companies. ... The biotech firm joins a group of health care companies advancing their IPO plans. Maze Theraupeutics Inc., which develops precision treatments for kidney, heart and metabolic ...

4 days ago · This morning also saw Maze Therapeutics outline plans for a $131 million IPO, while Hong Kong-listed Ascentage Pharma joined the Nasdaq via a $126.4 million offering on Friday.. Metsera plans to ...

3 days ago · The biotech IPO landscape gains momentum in 2025 as Aurion Biotech, Maze Therapeutics, and Metsera file for offerings. Aurion focuses on regenerative therapies, Maze advances precision medicines for kidney disease, and Metsera targets obesity with a GLP-1 agonist. The resurgence mirrors renewed investor interest in innovative therapeutics.

4 days ago · Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial public offering, set to be the first U.S.-based biotech firm to debut ...